Aarey Drugs & Pharmaceuticals reported a decline in FY26 income and profit while facing serious scrutiny from its secretarial auditor. Key concerns include non-disclosure of share warrants, penalties for missing regulatory filings, and irregularities in related party loans. Shareholders should note the governance gaps as the company prepares for its 36th Annual General Meeting on September 30, 2026.
Aarey Drugs & Pharmaceuticals Reports FY26 Results and Governance Challenges
Total Income stood at Rs. 478.37 crore against Rs. 483.76 crore in the previous fiscal, while Profit Before Tax dropped to Rs. 5.41 crore from Rs. 6.10 crore.
Reader Takeaway: Declining financial margins combined with material governance lapses present significant regulatory and operational risks for shareholders.
What just happened
Aarey Drugs & Pharmaceuticals has released its annual report ahead of its 36th Annual General Meeting, scheduled for September 30, 2026. The filing reveals a dip across major financial metrics, including a decline in EPS to Rs. 1.39. More pressingly, the secretarial audit report has highlighted several material governance and compliance issues.
Why this matters
The company’s internal control environment is under scrutiny. The audit report flagged the failure to disclose the allotment of 50 lakh warrants, lack of MGT-14 filings, and unauthorized loans to related parties without required special resolutions. These findings have already led to penalties from stock exchanges, signaling potential systemic weaknesses in administrative oversight.
Risks to watch
Investors should monitor the company's ability to rectify the identified filing deficiencies and address the digital database integrity issues. The breach of sections 185 and 188 of the Companies Act regarding related party loans remains a primary area of regulatory concern that could lead to further scrutiny or financial penalties.
What to track next
Shareholders should track the proceedings of the upcoming AGM, specifically regarding the approval of related party transactions and the management's response to the auditor's material observations. The company’s ability to stabilize its revenue growth and improve its regulatory filing track record will be critical for investor confidence.